Activists Broaden Efforts

Animal welfare activists, smarting from a defeat in Congress, plan to campaign across the United States to convince state legislators that laboratory rats, mice, and birds used in biomedical research require greater protection than afforded by federal law. Most major US research organizations, however, maintain that the 15 to 20 million animals used in labs--about 95% in biomedical research--are adequately protected under existing public and private regulations. More federal oversight, they sa

Written byTed Agres
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Animal welfare activists, smarting from a defeat in Congress, plan to campaign across the United States to convince state legislators that laboratory rats, mice, and birds used in biomedical research require greater protection than afforded by federal law. Most major US research organizations, however, maintain that the 15 to 20 million animals used in labs--about 95% in biomedical research--are adequately protected under existing public and private regulations. More federal oversight, they say, would only burden researchers with paperwork and expense while creating no real benefit for the animals.

The 2002 Omnibus Farm Bill, signed into law in May, included an amendment exempting "birds, rats of the genus Rattus, and mice of the genus Mus, bred for research" from the Animal Welfare Act. The AWA requires researchers to keep records by cage or by research protocol for most warm-blooded vertebrates, whereas records for cats, dogs, and nonhuman primates must be maintained ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies